Get started
Author

Shai Rubnov

Suppressors of Cancer Cell Proliferation from Fig (Ficus carica) Resin: Isolation and Structure Elucidation
2001 · Shai Rubnov, Yoel Kashman, et al. · Journal of Natural Products · 190
A Novel Substrate Mimetic Inhibitor of PKB/Akt Inhibits Prostate Cancer Tumor Growth in Mice by Blocking the PKB Pathway
2007 · Pninit Litman, Osnat Ohne, et al. · Biochemistry · 37
Echinosulfonic acid D: an ESI MS n evaluation of a new cytotoxic alkaloid from the New-Caledonian sponge Psammoclemma sp.
2004 · Shai Rubnov, Camille Chevallier, et al. · Natural Product Research · 25
Liquid chromatographic analysis of physostigmine salicylate and its degradation products
1999 · Shai Rubnov, Daniel Levy, et al. · Journal of Pharmaceutical and Biomedical Analysis · 16
Autocatalytic Degradation and Stability of Obidoxime
1999 · Shai Rubnov, Igor Shats, et al. · Journal of Pharmacy and Pharmacology · 11
Stability of Trimedoxime in Concentrated Acidic Injectable Solutions
1999 · Shai Rubnov, Shai Amisar, et al. · Military Medicine · 6
Glatiramer Acetate Depot (extended-release) phase IIa study in patients with Primary Progressive Multiple Sclerosis: safety and efficacy snapshot (1911)
2021 · Shlomo Flechter, Laura Popper, et al. · Neurology · 2
Glatiramer Acetate Depot (extended-release) Phase IIa one-year study in patients with Relapsing-remitting Multiple Sclerosis: Safety, tolerability and efficacy – NEDA Analysis (P6.359)
2018 · Ariel Miller, Laura Popper, et al. · Neurology · 2
GA Depot (Long-acting IM Injection of Glatiramer Acetate) Presents Improved Safety and Tolerability Features: Results from a Multinational, Double-blind, Placebo-controlled Phase III Study in Subjects with Relapsing Forms of Multiple Sclerosis (P8-6.018)
2024 · Aaron Miller, Laura Popper, et al. · Neurology · 1
Influence of trimedoxime bromide on degradation of benactyzine in acidic injectable solutions
1999 · Shai Rubnov, Shai Amisar, et al. · European Journal of Pharmaceutical Sciences · 1
GA Depot (Long-acting IM Glatiramer Acetate) and its Impact on EDSS in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) (P7-19.002)
2026 · Aaron Miller, Laura Popper, et al. · Neurology
GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial
2026 · Aaron Miller, Jeffrey A Cohen, et al. · Multiple Sclerosis Journal
PDF
1689-P: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks—Pharmacokinetic Modeling and Human-Based Allometric Scaling
2025 · SHAI RUBNOV, GALINA ZATS, et al. · Diabetes
GA Depot (Long-acting IM Injection of Glatiramer Acetate) Impact on EDSS Stability in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) (P11-1.014)
2025 · Aaron Miller, Laura Popper, et al. · Neurology
Glatiramer Acetate (ga) Long-acting Injection (ga Depot) Effect in a Mouse Model of Ibd
2025 · Nadav Bleich Kimelman, Shai Rubnov, et al. · Gastroenterology
Glatiramer Acetate (ga) Long-acting Injection (ga Depot) Effect in a Mouse Model of Ibd
2025 · Nadav Bleich Kimelman, Shai Rubnov, et al. · Inflammatory Bowel Diseases
2052-LB: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks, Demonstrates Similar Efficacy and PK Profile to Daily Semaglutide Administration
2024 · SHAI RUBNOV, GALINA ZATS, et al. · Diabetes
Oral Administration of a Novel Small Molecule Blocks the BMP Canonical and the Non-canonical BMP2, BMP4, and BMP5 Signaling Pathways Ameliorates EAE Through Oligodendrogenesis Remyelination and Preservation of Axonal Integrity and Reduces Astrogenesis (P7-6.015)
2024 · Maya Golan, Moshe Benhamou, et al. · Neurology
Results of a Phase III, Multinational, Double-blind, Placebo-controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis (RMS) to Assess the Efficacy, Safety, and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four Weeks (P6-3.014)
2023 · Aaron Miller, Laura Popper, et al. · Neurology
Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Primary Progressive Multiple Sclerosis: Safety and Efficacy Snapshot (P7-4.001)
2022 · Shlomo Flechter, Laura Popper, et al. · Neurology
Five Years Analysis of anti-Glatiramer Acetate (GA) Antibodies in Patients with Relapsing Remitting Multiple Sclerosis Treated with GA Depot (P5-4.010)
2022 · Shlomo Flechter, Ariel Miller, et al. · Neurology
Glatiramer Acetate Depot (extended-release) phase IIa study in patients with primary progressive multiple sclerosis: safety and efficacy snapshot (1956)
2020 · Shlomo Flechter, Laura Popper, et al. · Neurology
Glatiramer Acetate Depot (extended-release) phase IIa study in patients with relapsing remitting multiple sclerosis: safety, tolerability and efficacy (No Evidence of Disease Activity) subpopulation three-years analysis (1936)
2020 · Shlomo Flechter, Ariel Miller, et al. · Neurology
Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Relapsing Remitting Multiple Sclerosis: Safety, Tolerability and Efficacy (No Evidence of Disease Activity) Two-Years Analysis (P3.2-052)
2019 · Shlomo Flechter, Ariel Miller, et al. · Neurology
Pre-Clinical Studies and Evaluation of Treatment Need of Glatiramer Acetate Depot (Long Acting Injection) (P5.314)
2016 · Nadav Bleich Kimelman, Shai Rubnov, et al. · Neurology
Works count: 25
Citation count: 291
H-index: 6
I10-index: 5
Year
Topic
Type